Melexis and Graphenea Accelerate Graphene Biosensor Development
The partnership combines Melexis' semiconductor integration with Graphenea's expertise to create a scalable, integrated GFET-on-CMOS platform for advanced medical diagnostics and environmental sensing.
www.melexis.com
Graphenea Semiconductor, a leading graphene foundry company and Melexis, a global supplier of micro-electronic semiconductor solutions, announces a strategic collaboration to accelerate the development and evaluation of Melexis’ integrated GFET-on-CMOS platform for advanced biosensing.
The initiative aims to address some of the key hurdles in biosensor adoption: simplifying complex readout electronics and improving sensitivity while ensuring reliability and scalability. By combining Melexis’ expertise in semiconductor integration with Graphenea’s leadership in graphene transistors, the collaboration represents a crucial step from laboratory prototypes to real-world deployment. Applications span from medical diagnostics, such as cancer biomarker detection, neurological and infectious diseases detection, to broader biosensing applications like environmental sensing of PFAS.
"This collaboration with Melexis is a significant step forward for the biosensor field. Graphene has long been recognized for its extraordinary sensitivity, but system integration remained a challenge. Melexis’ GFET-on-CMOS platform bridges that gap, and together we are laying the foundation for practical, reliable graphene-based diagnostic tools,” said Jesus de la Fuente, CEO of Graphenea Semiconductor.
www.melexis.com
